August 12, 2021

Cipla has received final approval from the U.S. FDA for its generic version of Durezol® (difluprednate ophthalmic emulsion – Novartis) 0.5%.

A topical corticosteroid, difluprednate ophthalmic emulsion is indicated to treat inflammation and pain associated with eye surgery and for treatment of endogenous anterior uveitis – an inflammatory disorder of the eye that occurs when there are no known infections or external causes for inflammation, such as physical trauma.

Recommended dosing for uveitis is one drop into the affected eye, placed in the pocket between the lower eyelid and the eye, four times daily for two weeks. Dosing is then tapered off as instructed by the prescriber. For post-surgical use, the medication is administered four times a day for two weeks, then twice daily for another week.

Pricing for Cipla’s generic is not yet available.

September 2, 2021

Pfizer Adds Four Lots to Chantix Recall

Read More
September 2, 2021

Drizalma Sprinkle Receives New Indication for Fibromyalgia

Read More
September 2, 2021

Opdivo Loses Indication as Single-Agent Treatment for Liver Cancer

Read More
August 18, 2021

Jardiance Receives New Heart Failure Indication

Read More